Janux stock plunges after hours following mCRPC trial data
Investing.com -- BillionToOne received a wave of upbeat Wall Street initiations as analysts highlighted the company’s proprietary DNA detection technology and early traction in prenatal and oncology testing.
But two firms struck a more cautious tone on valuation.
Piper Sandler and JPMorgan both launched coverage with Overweight ratings and $150 price targets, pointing to the company’s ability to detect genetic material at extremely low concentrations.
Piper Sandler’s David Westenberg said BillionToOne “built a platform to capture targeted molecules at single count levels and remove artifacts before amplification,” enabling what he called “leading error correction technology.”
He said this approach should support “a 25%+ revenue CAGR in reproductive health,” with oncologists suggesting its tumour-focused testing could be “game-changing.”
JPMorgan analyst Casey Woodring echoed the bullish outlook, saying BLLN’s smNGS platform allows direct fetal risk assessment and “provides therapy selection insights and real-time monitoring of patient response.”
He projected a 29% revenue CAGR from 2025 to 2030 and said a competitive tissue-free MRD test expected in 2026 supports further growth. Despite the stock’s 117% year-to-date rally, Woodring said he “likes the set up for the stock over time.”
Stifel also initiated at Buy with a $145 target. Analyst Daniel Arias said the company is taking share in non-invasive prenatal testing thanks to “meaningful performance and workflow advantages,” adding that early oncology volumes “look promising” and that BLLN is already profitable “in a way that peers won’t be for years.”
Meanwhile, Jefferies urged restraint. Analyst Tycho Peterson initiated with a Hold and a $117 target, noting shares had doubled since the IPO.
He said the company’s highly sensitive assays support “outsized growth (>40% CAGR through ’28)” but added that the stock already trades at “12x ’26 sales.”
Elsewhere, Wells Fargo was also more cautious, initiating the stock with an Equal Weight rating and $110 price target, telling investors that “ BLLN now trades at a substantial premium vs. peers.”